2024
The Abundance of KRAS and RAS Gene Mutations in Cancer
Stites E. The Abundance of KRAS and RAS Gene Mutations in Cancer. Methods In Molecular Biology 2024, 2797: 13-22. PMID: 38570449, DOI: 10.1007/978-1-0716-3822-4_2.Peer-Reviewed Original Research
2023
Computational Random Mutagenesis to Investigate RAS Mutant Signaling
Stites E. Computational Random Mutagenesis to Investigate RAS Mutant Signaling. Methods In Molecular Biology 2023, 2634: 329-335. PMID: 37074586, PMCID: PMC10530643, DOI: 10.1007/978-1-0716-3008-2_15.Peer-Reviewed Original Research
2021
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
McFall T, Stites E. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Reports 2021, 37: 110096. PMID: 34910921, PMCID: PMC8867612, DOI: 10.1016/j.celrep.2021.110096.Peer-Reviewed Original ResearchConceptsSensitivity to EGFR inhibitionSubsets of mutationsRAS mutationsKRAS G13DCancer cell biologyEGFR inhibitionEpidermal growth factor receptor (EGFR)-targeted therapyTumor suppressor neurofibrominGene-basedBiophysical biomarkersInhibitor sensitivityCell biologyMutationsPersonalized medicineBiomarker strategiesKRAS mutantRasCancer treatmentKRASNF1BiomarkersBiophysical characteristicsG13DMutantsInhibition
2018
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect
Rauen K, Schoyer L, Schill L, Stronach B, Albeck J, Andresen B, Cavé H, Ellis M, Fruchtman S, Gelb B, Gibson C, Gripp K, Hefner E, Huang W, Itkin M, Kerr B, Linardic C, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson D, Stites E, Stork P, Sun C, Therrien M, Ullian E, Widemann B, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. American Journal Of Medical Genetics Part A 2018, 176: 2924-2929. PMID: 30302932, PMCID: PMC6312476, DOI: 10.1002/ajmg.a.40632.Peer-Reviewed Original ResearchConceptsGerm line mutationsPredisposition to cancerSomatic malignancyOcular abnormalitiesCraniofacial dysmorphologyMalformation syndromePathogenetic etiologyRas/mitogen-activated protein kinasePathogenetic mechanismsEffects of dysregulationSomatic cancersOncogenic pathwaysCancerPhenotypic featuresRASopathiesMAPK pathwayRas pathwayNormal functionEncode componentsProtein kinaseNeurocognitive issuesExcellent modelPathwayMalignancy
2012
Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer J, Legendre C, Posner R, Hostetter G, Baker A, Egan J, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Von Hoff D. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLOS ONE 2012, 7: e43192. PMID: 23071490, PMCID: PMC3468610, DOI: 10.1371/journal.pone.0043192.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBase SequenceBRCA2 ProteinDNA RepairFemaleGene DosageGenome, HumanHigh-Throughput Nucleotide SequencingHumansMaleMetabolic Networks and PathwaysPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Ras ProteinsSequence Analysis, RNATranscriptomeTumor Suppressor Protein p53ConceptsPancreatic adenocarcinoma patientsNext generation sequencingPancreatic adenocarcinomaGeneration sequencingSomatic eventsGenome-wide characterizationChromosomal copy number variantsCopy number variantsImproved therapeutic selectivityTumor suppressive pathwaysPancreatic adenocarcinoma tumorigenesisTumor-stroma interactionsKRAS signaling pathwaySequence dataTranscriptomic informationTumor/normal samplesEvaluate expression changesTranslocation eventsMultiple genesPoint mutationsRNA sequencingMapped readsPatient tumorsAdenocarcinoma patientsPathway analysisMathematical Investigation of How Oncogenic Ras Mutants Promote Ras Signaling
Stites E, Ravichandran K. Mathematical Investigation of How Oncogenic Ras Mutants Promote Ras Signaling. Methods In Molecular Biology 2012, 880: 69-85. PMID: 23361982, DOI: 10.1007/978-1-61779-833-7_5.Peer-Reviewed Original Research
2011
Mechanistic modeling to investigate signaling by oncogenic Ras mutants
Stites E, Ravichandran K. Mechanistic modeling to investigate signaling by oncogenic Ras mutants. WIREs Mechanisms Of Disease 2011, 4: 117-127. PMID: 21766467, DOI: 10.1002/wsbm.156.Peer-Reviewed Original ResearchMeSH KeywordsCell CommunicationHumansModels, GeneticMutationNeoplasmsOncogenesRas ProteinsSignal TransductionConceptsCell signaling networksSignaling networksCancer phenotypeMutant Ras signalingAcquisition of mutationsRas signalingCell signalingBiochemistry of proteinsLevel of signalMutated genesExpression levelsBiochemical reaction mechanismsPhenotypeMechanistic modelInvestigated signalSignalGenesMutationsRasProteinCancerIndividual reactionsExpression
2010
Modeling Membrane Localization: Case Study of a Ras Signaling Model
Stites E. Modeling Membrane Localization: Case Study of a Ras Signaling Model. Advances In Experimental Medicine And Biology 2010, 680: 661-667. PMID: 20865552, DOI: 10.1007/978-1-4419-5913-3_73.Peer-Reviewed Original Research
2007
Network Analysis of Oncogenic Ras Activation in Cancer
Stites E, Trampont P, Ma Z, Ravichandran K. Network Analysis of Oncogenic Ras Activation in Cancer. Science 2007, 318: 463-467. PMID: 17947584, DOI: 10.1126/science.1144642.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCell LineCell Line, TumorCell Transformation, NeoplasticComputer SimulationExtracellular Signal-Regulated MAP KinasesGenes, rasGTP PhosphohydrolasesGTPase-Activating ProteinsGuanosine DiphosphateGuanosine TriphosphateHumansMathematicsMetabolic Networks and PathwaysModels, BiologicalNeoplasmsPhosphorylationPoint MutationRas ProteinsSignal Transduction